Ondansetron: Reasons to be restrictive [6]

Lancet

Volumn 347, Issue 9013, 1996, Pages 1484-1485

  Frigerio, C ^a   Buchwalder, P A ^a   Spertini, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CLEMASTINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; HYDROCORTISONE; ONDANSETRON; SEROTONIN ANTAGONIST; VINBLASTINE;

ADULT; CASE REPORT; CLINICAL FEATURE; COUGHING; DYSPNEA; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; MALE; NAUSEA; PRIORITY JOURNAL; SKIN TEST; THORAX PAIN;

EID: 0029945031     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91720-1     Document Type: Letter

References (5)

1. Pj Hesket Wk Murphy Ep Lester GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis J Clin Oncol 7 1989 700 705
2. M. Chen A. Tanner H. Gallo-Torres Anaphylactoid-anaphylactic reactions associated with ondansetron Ann Intern Med 119 1993 862
3. Hs Ballard G. Bottino J. Bottino Ondansetron and chest pain Lancet 340 1992 1107
4. Bw Cromar M. Colvin Tb Casale Validity of skin tests to cyclophosphamide and metabolites J Allergy Clin Immunol 88 1991 965 967
5. 3-receptor antagonist: a class effect? Lancet 347 1996 584 585